0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessPurpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate early detection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study.
Experimental Design: We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis.
Results: We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker.
Conclusions: CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases. Clin Cancer Res; 22(18); 4664–75. ©2016 AACR.
See related commentary by Skates, p. 4542
Kathryn L. Terry, Helena Schöck, Renée T. Fortner, Anika Hüsing, Raina N. Fichorova, Hidemi S. Yamamoto, Allison F. Vitonis, Theron Johnson, Kim Overvad, Anne Tjønneland, Marie‐Christine Boutron‐Ruault, Sylvie Mesrine, Gianluca Severi, Laure Dossus, Sabina Rinaldi, Heiner Boeing, Vassiliki Benetou, Παγώνα Λάγιου, Antonia Trichopoulou, Vittorio Krogh, Elisabetta Kuhn, Salvatore Panico, H. Bas Bueno‐de‐Mesquita, N. Charlotte Onland‐Moret, Petra H. Peeters, Inger Torhild Gram, Elisabete Weiderpass, Eric J. Duell, María‐José Sánchez, Eva Ardanáz, Nerea Etxezarreta, Carmen Navarro, Annika Idahl, Eva Lundin, Karin Jirström, Jonas Manjer, Nicholas J. Wareham, Kay‐Tee Khaw, Karl Smith-Byrne, Ruth C. Travis, Marc J. Gunter, Melissa A. Merritt, Elio Riboli, Daniel W. Cramer, Rudolf Kaaks (2023). Data from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. , DOI: https://doi.org/10.1158/1078-0432.c.6525378.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Preprint
Year
2023
Authors
45
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1158/1078-0432.c.6525378
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
